Tolerance to opioid administration represents a serious medical alert in different chronic 28
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Male Wistar rats (Harlan, S. Pietro al Natisone, UD, Italy) weighing 250-300 g were housed 104
with ad libitum access to food and water, in a temperature-controlled room with a 12-hour 105 light/dark cycle. All the experimental procedures described were in compliance with 106 international laws and policies (Directive 2010/63/EU revising Directive 86/609/EEC on the 107 protection of animals used for scientific purposes; Guide for the Care and Use of Laboratory 108 Animals, U.S. National Research Council, 1996) . 109 Basile, VA, Italy) before CFA injection (healthy animal basal threshold), 24 hours after CFA 116 injection (inflamed paw basal threshold) and at different time after drugs administration. 117
Analgesic assay 110
Morphine tolerance was induced by administering morphine 5 mg/kg subcutaneously (s.c.), 118 twice a day, for 4 consecutive days after CFA induced inflammation in the paw. To assess the 119 effects on morphine tolerance, 1-3 were administered twice a day for 4 days at a dose of 0.5 120 mg/kg intraperitoneally (i.p.) 15 min before morphine. 121
Unless otherwise noted, all experimental and control groups contained six animals per group. 122
Antinociceptive effect was expressed as percent of the maximum possible effect (MPE) 123 according to the following formula: %MPE = (measured threshold -mean vehicle 124 threshold/cut off -mean vehicle threshold) x 100. All data were expressed as mean ± S.E.M. for each concentration were performed, and the relative standard deviations (RSDs) ranged 166 from 1.1 to 2.2% for run-to-run precision, and from 3.0 to 4.7 % for day-by day precision. 167
The calibration curves of the analyzed compounds showed a correlation coefficient equal to 168 1.0000 (1) and 0.9995 (2). The LOD and LOQ, defined as the peak giving a response equal to 169 a blank signal plus three and ten times the standard deviation of the noise were calculated, 170 respectively. The LODs and the LOQs of the studied compounds, expressed in ng ml -1 , were 171 calculated injecting in LC/MS standard solutions of both analytes at various concentrations. 172
LODs value for 1 and 2 was 1 ng ml -1 , while LOQs value for 1 and 2 was 3 ng ml -1 . The 173 recovery percentages of 1 and 2 were investigated by spiking with the standard mixture of 1 174 and 2 the plasma samples before extraction, for a final concentration level of 5, 10 and 50 ng 175 ml -1 . Mean recoveries of the two compounds ranged from 88 to 92% with n = 5 and RSDs 176 <4.3% for plasma samples. Retention time stability was utilized to demonstrate the specificity9 of the method. Reproducibility of the chromatographic retention time for each compound was 178 examined five times per day over a 5-day period (n = 25). The retention times using this 179 method were stable with a percent RSD value of ≤1.82%. (Fig. 2) . However, after 4 days of twice-daily administration, rats had become 196 completely tolerant to morphine. Thus, 5 mg/kg morphine was found to be completely 197 inactive at day 4 (Fig. 2) . minor extent (35-40%) the morphine response but, in this case, the maximal activity was 205 observed at t=90 min (p<0.05 vs. vehicle; Dunnett's multiple comparisons test) (Fig. 3) . 206
Since the different temporal profile on the tolerance reduction displayed by 1-3 might be 207 associated not only to their different target profile, but also to their bioavailability, we 208 developed an HPLC-mass spectrometry method for the determination of the ligand levels in 209 the rat plasma. In particular, due to the similar behaviour showed by the structural analogues 1 210 and 3 in the tolerance reduction assays, only 1 and 2 have been selected for pharmacokinetic 211 studies. In rat plasma, the mean serum concentration of 1 was determined to be maximum at 212 60 minutes (14.71 ± 0.28 ng/ml; n=3). At 30 and 90 minutes, mean concentrations of 9.48 ± 213 0.04 ng/ml and 8.26 ± 0.08 ng/ml, respectively, have been found. The mean serum 214 concentration of 2 was determined to be maximum at 30 minutes (58.00 ± 3.11 ng/ml; n=3). 215
At 60 and 90 minutes, 2 was not found in rat plasma samples, showing a faster 216 pharmacokinetic profile vs. 1 (Fig. 4) . Plasma samples were performed in triplicate, with 217 RSDs% lower than 1.88% and 5.36% for 1 and 2, respectively. 218 In particular, the -OCH(CH 3 )-bridge was suitable for ligands showing significant α 2 -229 adrenoceptor/imidazoline I 2 receptor selectivity (e.g. 1, allyphenyline) ( Table 1 ). The 230 presence of the methyl group in the bridge strongly disadvantaged the I 2 receptor interaction 231 (Gentili et al., 2003) . Conversely, the -CH 2 -CH 2 -bridge provided ligands endowed with high 232 I 2 receptor affinity and high selectivity over the α 2 -adrenoceptors (e.g. 2) (Gentili et al., 2003 (Gentili et al., , 233 2008a ). On the other hand, the I 2 receptor/α 2 -adrenoceptor selectivity of 2 has been also 234 confirmed by our study performed on α 2A -, α 2B -, and α 2C subtypes (data unpublished). Finally, 235 the -OCH 2 -bridge appeared compatible with α 2 -adrenoceptor and I 2 receptor recognition (e.g. The present study, showing the ability of 1-3 to significantly reduce the induction of 255 morphine tolerance, confirms the favourable involvement of α 2C -adrenoceptor agonism and 256 imidazoline I 2 receptor interaction in such an effect. Interestingly, the sub-chronic treatment 257 with 2 significantly restored the lost morphine analgesic efficacy (65-70%) by maintaining the 258 same time-dependent profile displayed after a single morphine administration on day 1. 259 Indeed, the analgesic response was maximal at t=45 min and negligible at t=90 min. (Fig. 3) . 260
Conversely, in the case of 1 and 3 the morphine analgesic response was restored at minor 261 extent (35-40%) but it proved to be significantly prolonged, the maximal activity being 262 observed at t=90 min (Fig. 3) . 263
The modulation of morphine tolerance resulted to be not related to the morphine analgesia 264 enhancement. Indeed, though on a classical acute paradigm of pain on healthy animals 265 allyphenyline (1) significantly enhanced morphine analgesia (Cardinaletti et al., 2009) Interestingly, the pharmacodynamic behaviours of the studied compounds evidenced an 272 activity pattern that was in keeping with their pharmacokinetic profile. In fact, according to 273 the biological results, in rat plasma the mean serum concentration was maximum at 30 274 minutes (58.00 ± 3.11 ng/ml) for 2 and at 60 minutes (14.71 ± 0.28 ng/ml) for 1 (Fig. 4) . This 275 observation suggested that the different temporal profile displayed on the tolerance reduction 276 could be affected by their different bioavailability. However, the role played by the peculiar in 277 13 vitro biological profile of the ligand in its pharmacological effect should be also considered. 278
Indeed, whereas the selective engagement of the imidazoline I 2 receptors produced by 2 might 279 contribute to induce an almost full restoring of morphine activity, the selective α 2C -280 adrenoreceptor activation induced by 1 or the combination between α 2C -adrenoreceptor 281 activation and imidazoline I 2 receptors engagement (3) might promote a change in the 282 temporal profile of morphine analgesia by maintaining a mild but long lasting analgesic 283 effect. However, for compound 3 a slight tendency to provide a more prolonged effect can 284 also be observed (Fig. 3) . 285
These results deserve to be replicated in follow-up studies by using animal models of chronic 286 pain resembling closer those human conditions that need morphine or other opioid drugs as 287 the only available drugs able to alleviate pain. 
